Author response: Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
Youyou Zhang(University of Pennsylvania), Xiaowen Hu(Lanzhou University), János L. Tanyi(Penn Center for AIDS Research), Robert H. Vonderheide(University of Pennsylvania), Jie Huang(Institute for Reproductive Health), Sarah H. Kim(Memorial Sloan Kettering Cancer Center), Omid Tavana(Bioscience Research), Meixiao Long(The Ohio State University), Jianfeng Shen(Shanghai Jiao Tong University), Bingwei Wang(Nanjing University of Chinese Medicine), Lin Zhang(Simon Fraser University), Yi Fan(Academy of Military Medical Sciences), Jiao Yuan(AstraZeneca (South Korea)), Yanrong Sun(Peking University), Mu Xu(AstraZeneca (South Korea)), Yuxin Wang, Kathleen T. Montone, Ho Man Chan, Junjie Jiang(Wuhan Children's Hospital), Susan M. Domchek(University of Pennsylvania), Zhongyi Hu(AstraZeneca (South Korea))
Cited by 0
Related Papers
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
|Nature|2016|925
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
|Cancer Immunology Research|2015|467
A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation
|Nature Cell Biology|2018|435